TNFRSF11A and cancer: However, recent understanding of the oncogenesis of breast cancer (BRCA)‐related cancers has suggested that modifying the receptor activator of nuclear factor‐κB (RANK) ligand pathway with the drug denosumab may prevent cancer formation,10 and a clinical trial (BRCA‐P)11 is underway to test this hypothesis.